

Special Issue

NK Cells in the Tumor Microenvironment: Immunosuppressive Mechanisms and Therapy

Message from the Guest Editors

Natural killer (NK) cells represent the innate counterparts of cytotoxic T lymphocytes, poised to rapidly engage in cell-mediated cytotoxicity and the release of potent proinflammatory cytokines. Their functions are largely regulated through surface-activating and inhibitory receptors which probe their tissue microenvironment for signs of infection or malignancy. Therapeutic manipulation of these opposing receptors holds great promise for clinical intervention. In this Special Issue, we explore the mechanisms malignant cells employ to inhibit NK cell surveillance, as well as therapeutic strategies to overcome these immunosuppressive pathways and enhance NK cell activity.

Guest Editors

Dr. Alexander Barrow

Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia

Dr. Julian Vivian

1. St. Vincent's Institute of Medical Research, Fitzroy, VIC, Australia
2. Department of Medicine, The University of Melbourne, Melbourne, VIC, Australia

Deadline for manuscript submissions

30 June 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/196123

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)